PArtial REbreathing for Migraine with Aura

Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life.Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment.

This indicates a large unmet clinical need and a significant commercial potential.The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system.

The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.